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Abstract
Introduction: Chronic pain classification in HIV positive patients is essential for diagnosis and treatment. However, this is rarely 
done despite association with poor outcomes.
Methods: A cross-sectional survey of  345 consented patients at a specialized HIV care center in Uganda was conducted. Chron-
ic pain was defined as pain of  more than two weeks duration. Data was collected using a socio-demographic questionnaire, the 
IASP classification of  chronic pain; the StEP; Mini Mental Status Examination, Patient Health Questionnaire, Mini International 
Neuropsychiatric Interview and the World Health Organization quality of  life instrument brief  version. Chi-square, Fisher’s 
exact, t-test and logistic regression analyses were carried out to determine factors associated with chronic pain.
Results: Description of  pain aetiology was difficult. Chronic pain was reported in 21.5% of  the participants. Non-neuropathic 
(92.0%) was more common than neuropathic pain (8.0%). Chronic pain was found to be associated with feeling ill [OR=6.57 
(3.48 – 12.39)], and worse scores in the quality of  life domain for physical health [OR=0.71 (0.60 – 0.83)].
Conclusion: People living with HIV/AIDS commonly have chronic pain that is associated with poor quality of  life. More sen-
sitive tools are needed to accurately describe chronic pain in resource limited settings.
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Introduction
Pain in its simplest classification may be described as ei-
ther acute pain (AP) or chronic pain (CP)1. AP may be 
nociceptive or inflammatory pain2,3 and is provoked by a 
specific disease or injury, serves a useful biologic purpose 
and is self-limited4. CP has also been described as patho-
logical pain2 and includes dysfunctional and neuropathic 
pain2,3. It has been argued to be a disease in and of  itself  
with clear pathology, symptom patterns and management 
approaches which are different to acute pain5. It is pain 
that outlasts the normal time of  healing, if  associated 
with a disease or injury. CP may arise from psychological 
states, serves no biologic purpose, and has no recogniz-
able end-point.Different pain classifications have differ-
ent mechanisms and therefore require different manage-
ment strategies.
The literature on pain classification tools for the de-
scription of  pain among people living with HIV/AIDS 
(PLWHA) is limited and inconsistent6-8. The majority of  
literature from sub Saharan Africa has described AP6,9-14. 
Literature on AP among PLWHA reveals that it is both 
common and burdensome6,8,13,15. AP has also consistently 
been associated with increased drug use, poor quality of  
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life (QOL) and increased morbidity and mortality9,16. Sim-
ilar literature on descriptions and factors associated with 
CP among PLWHA from sub Saharan Africa is limited 
and inconsistent.
CP among PLWHA may be argued to be  a syndrome 
due to its marked diversity to  involve various regions, 
systems, intensities, characteristics, etiologies and a host 
of  co morbidities like substance use and depression7,10,12. 
The prevalence rates and factors associated with CP may 
differ from those of  acute pain in PLWHA as CP per-
sists beyond normal healing time of  the causative mech-
anism. Also, because CP is persistent it might have worse 
outcomes on various morbidity statistics like quality of  
life. Factors that have been associated with AP in PWHA 
like immune status and HAART regimens <="" span="" 
style="font-family: "Times New Roman";">The current 
literature on pain in PLWHA has dwelt on AP and as 
such not many tools areavailable to describe CP. Tools 
like the Neuropathic Pain Scale that are available for de-
scribing CP are limited inuse given that they are valid for 
only specific types of  pain17. CP in PLWHA however has 
been found to beheterogeneous affecting various sites at 
different intensities and by various mechanisms7,13,18.To 
ensure better management of  CP in PLWHA better de-
scription of  CP is required. A clearer  description of  CP 
in PLWHA improvesour understanding of  mechanisms 
that can enable one to suggest appropriate treatments. 
Classification and description of  CP allows specialists to 
group conditions in order to better understand disease 
mechanisms1 and to improve on management strategies.  
In this report, we characterised CP using the Internation-
al Association for the Study of  Pain (IASP) classification 
of  chronic pain; and the Standardised Evaluation of  Pain 
(StEP). We also described the factors associated with CP 
among HIV positive patients attending a centre of  excel-
lence for HIV care in Uganda.
Methods
Study design and setting: This was a cross-section-
al study done at Mildmay Uganda which is a specialised 
HIV care centre located at Lweza, 12 km from the Ugan-
dan capital. It was officially opened in 1998 as a Centre of  
Excellence for provision of  comprehensive HIV & AIDS 
prevention, care, treatment and training service. As one 
of  the oldest HIVcare centres in the country, it reviews 
over 200 patients a day on an out-patient basis at Lweza. 
It also has satellite clinicsin 16 districts around the coun-
try offering specialised HIV care. At the centre, it runs 
daily offering general care to patients but also has special-
ist clinics on specific days in the week. A psychiatry clinic 
is run every Tuesday by aconsultant psychiatrist.
Ethical approval: Approval for the study was obtained 
from the Makerere University College of  Health Scienc-
es, School of  Medicine Research and Ethics Committee, 
Mildmay Uganda Research and Ethics Committee and 
the Uganda National Council of  Science and Technology. 
No individual participant data is reported.
Chronic pain measures
CP classification was done using the IASP, classification 
of  Chronic pain19 and the Standardized Evaluation of  
Pain was designed by Scholz et al20. CP was described as 
pain of  more than two weeks duration. A duration of  two 
weeks was used to avoid documenting acute pain which is 
defined as “the normal, predicted physiological response 
to an adverse chemical, thermal or mechanical stimulus 
associated with surgery, trauma and acute illness21.” Most 
tools that assess for acute pain describe it as pain of  one 
week duration. The  IASP classification on the other hand 
classifies acute pain as pain of  less than one month19. The 
decision of  two weeks was made to exclude acute pain 
but allowed for all pain durations using the IASP classifi-
cation of  chronic pain.
The IASP classification describes pain according to five 
different axes. Axis I records the region of  the body af-
fected while axis II records the system involved. Temporal 
characteristics of  pain and pattern of  occurrence are re-
corded on axis III. Axis IV records the patient’s statement 
of  intensity and time since onset of  pain with aetiology of  
the pain recorded on axis V. Total scores were then added 
to generate a five digit code that is correlated to a specific 
diagnosis of  known pathophysiology. Scores of  axis IV 
are not considered in generating diagnostic codes due to 
the variability of  patient’s perception of  pain intensities 
and also to account for recall bias in noting the correct 
duration of  pain22. Patient codes that were exactly similar 
to codes in the manual were matched to known diagnoses 
in the classification manual and reported. Not all codes in 
the IASP classification have been awarded corresponding 
codes for diagnoses of  known pathophysiology at this 
time and as such some pains might be unclassified for 
now. Generated codes that could not be matched to any 
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code in the manual were reported as ‘unallocated codes.’ 
If  codes differed only in the etiological mechanisms but 
had similar classifications of  region system and temporal 
characteristics, ‘differing etiology’ was reported after con-
firming that the code would have been generated was an 
unallocated code in the IASP classification.
The Standardized Evaluation of  Pain was designed by 
Scholz et al20 It is used to differentiate neuropathic from 
non neuropathic pain and has been validated in patients 
with chronic back pain. It has been found to have better 
sensitivity and specificity than the DN418 for screening 
for neuropathic pain. In this study, it was used to gener-
ate scores that differentiate neuropathic from non neu-
ropathic pain. Total scores of  more than 4 from all the 
questions are suggestive of  neuropathic pain while scores 
of  four and below are indicative of  non neuropathic pain.
Study procedure: All recruited adult patients receiving 
care from Mildmay Uganda centre at Lweza who con-
sented to the study made up the sampling frame. We ini-
tially assessed for cognitive impairment using the mini 
mentalstatus examination (MMSE). We included patients 
in care above 18 years of  age and excluded those MMSE 
scores less than or equal to 19. We also excluded par-
ticipants too ill to participate or those who needed re-
ferral for inpatient care. Using Leslie Kish formula23 we 
estimated asample size of  three hundred and eighty one 
participants at a precision of  5% and anticipated prev-
alence of  42.8% based on a study by Miaskowski et al 
201124, depressive episode using the Patient Health Ques-
tionnaire (PHQ)25 and confirmed using the MINI Inter-
national Neuropsychiatric Inventory (MINI) (26). Finally, 
data extraction from patients medical records was done 
for CD4 counts, HAART regimens and past treatment 
or diagnosis for pain and depression. Data was collected 
over a four month period between September 2013 and 
December 2013.
Data analysis: Data was analyzed using STATA Version 
12 (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP). Participants with CP 
were assigned diagnoses according to the IASP classii-
cation and StEP. To test for associations, the dependent 
variable was the presence of  CP. Socio-demographic fac-
tors, clinical characteristics, quality of  life and depression 
status were the independent variables. Chi-square, Fisher’s 
exact and t-tests were carried out to identify potential fac-
tors associated with CP. The factors with p-value <0.25 
were then entered into a multiple logistic regression and 
model building done using a likelihood ratio test. In case 
of  correlated independent variables (multi co linearity 
problem) mean centering was done. This is a statistical 
method to deal with collinearity which involves subtract-
ing the mean from all data points therefore shifting the 
scale of  the variable and is usually applied to predictors27. 
If  centering did not solve the problem, then one of  the 
correlated variables explaining the larger variability, that 
is, the one with a smaller bi-variable p value was retained.
Results
Between September and December 2013, 373 patients 
were invited to participate in the study. Six participants 
were excluded due to severe cognitive impairment 
(MMSE scores <19). After cleaning of  data by remov-
al of  duplicates and incomplete records, 345 records re-
mained for analysis.
Seventy four out of  the 345 participants (21.5%) report-
ed having CP. The majority 69/74 (93.2%) reported pain 
at only one site. For participants who reported CP, the 
mean age was 38.6 (SD=9.9) years while mean scores for 
cognitive function on the MMSE were 27.6 (SD=2.9). 
The few patients not on HAART (15/74) were receiv-
ing daily septrin prophylaxis. The median CD4 count 
was 376 cells/mm3 (IQR: 256 - 581) and 49 participants 
(66.2%) reported currently feeling ill primarily with pain 
related complaints. There were no differences in terms of  
gender, marital status, level of  education or age for those 
with chronic pain.  More results are shown in table I.
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Among the 69 participants who reported pain at one site, 
the region (axis I) most affected was the lower back re-
gion 18/69 (26.1%). For axis II (system), the musculo-
skeletal system was most affected with 43/69 (62.3%). 
No pain was associated to more than two systems. For 
axis III (Temporal Characteristics of  Pain: Pattern of  
Occurrence) 27/69 (39.1%) reported pain that was re-
curring irregularly.  A total of  20/69 (29.0%) reported 
pain of  medium intensity of  1 to 6 months duration on 
axis IV (Patient’s Statement of  Intensity: Time since On-
set of  Pain). Axis V (Aetiology) was hard to determine 
with 41/69 (59.4%) of  the participants having their pain 
reported as unknown or other on axis V. Additional de-
scriptive statistics are shown in table 2.









Moderate 46 (13.33) 14 (18.92) 32 (11.85)
Mild 44 (12.75) 9 (12.16) 35 (12.96)
Normal 255 (73.91) 51 (68.92) 203 (75.19)
Reported ill 0.000
Yes 92 (26.67) 49 (66.22) 43 (15.93)
No 253 (73.33) 25 (33.78) 227 (84.07)
Immunological stage 0.978
Severe (<200cells/mm3) 58 (17.47) 14 (18.92) 44 (17.12)
Advanced (200-349cells/mm3) 74 (22.29) 17 (22.97) 57 (22.18)
Mild (350-499cells/mm3) 67 (20.18) 14 (18.92) 52 (20.23)
Not significant (>500cells/mm3) 133 (40.06) 29 (39.19) 104 (40.47)
On HAART 0.268
Yes 287 (83.92) 59 (79.73) 228 (85.07)
No 55 (16.08) 15 (20.27) 40 (14.93)
Prior Depression Diagnosis 0.528
Yes 14 (4.11) 4 (5.41) 10 (3.76)
No 326 (95.82) 70 (94.59) 256 (96.24)
Prior Pain Diagnosis 0.005
Yes 19 (5.57) 9 (12.16) 10 (3.76)
No 321 (94.41) 65 (87.84) 256 (96.24)
Major Depressive Episode 0.000
Yes 34 (10.97) 17 (22.97) 17 (6.30)
No 310 (89.03) 57 (77.03) 253 (93.70)
HAART Regimen 0.798
None 56 (16.23) 15 (20.27) 41 (15.19)
AZT based regimen 134(38.84) 24 (32.43) 109 (40.37)
TDF based regimen 141 (40.87) 32 (4.24) 109 (40.37)




None 327 (95.89) 71 (94.59) 256 (96.24)
Yes 14 (4.11) 4 (5.41) 10 (3.76)
Previous pain treatment 0.033
None
Yes
323 (94.44) 66 (89.19) 256 (95.88)
18 (5.56) 8 (10.81) 11 (4.12)
Quality of life (Mean, SD)
Physical Health
Psychological
15.43 (2.20) 13.58(2.75) 15.94(1.71) 0.000
16.16 (2.16) 15.14(2.82) 16.31(1.87) 0.000
Social relationships 13.78 (2.99) 13.91(2.97) 13.74(3.00) 0.662
Environment 14.68 (1.83) 13.81(2.24) 14.91(1.63) 0.000
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Table 2: IASP classification of chronic pain at one pain site.
Characteristic Frequency Percentage (%)
Region Lower back, lumbar spine, sacrum and 
coccyx
18 26.1
Lower limbs 12 17.4
Upper shoulder and limbs 10 14.5
Head face and mouth 9 13.0
Thoracic region 9 13.0
Abdominal region 7 10.1
Cervical region 2 2.9
Anal, perianal and genital region





System Musculoskeletal system and connective 
tissue
43 62.3
Gastrointestinal system 9 13.0
Nervous system (central, peripheral, and 
autonomic) and special senses; physical  
disturbance or dysfunction  
8 11.6
Cutaneous and subcutaneous and associated 
glands (breast, apocrine, etc.)
4 5.8
Respiratory and cardiovascular systems 3 4.4
Genito-urinary system 2 2.9
Temporal Characteristics of Pain: Pattern of 
Occurrence
Recurring irregularly 27 39.1
Continuous or nearly continuous, 
fluctuating severity
13 18.8
Other combinations 11 15.9
Recurring regularly 9 13.0
Continuous or nearly continuous, 
nonfluctuating
6 8.7
None of the above 2 2.9
Paroxysmal 1 1.4
Patient’s Statement of Intensity: Time Since 
Onset of Pain
Medium-1 month to 6 months     . 20 29.0
Medium -more than 6 months 15 21.7
Severe- more than 6 months 11 15.9
Mild -I month or less  9 13.0
Severe- 1 month to 6 months 7 10.1
Severe- 1 month or less 4 5.8
Not recorded, not applicable, or not known 2 2.9
Medium -1 month or less  1 1.4
Aetiology Unknown or other 41 59.4
Inflammatory, immune reactions 8 11.6
Infective, parasitic 5 7.2
Degenerative, mechanical 5 7.2
Toxic, metabolic (e.g., alcoholic 
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having ‘unallocated codes’ and 30/74 (40.5%) had codes 
with ‘differing aetiology.’
Table 3 summarises the participants who had codes as per 
the IASP manual and their corresponding scores on StEP. 
(<4 implies non-neuropathic pain and >4 implies neuro-
pathic pain). There was more non-neuropathic (92.0%) 
than neuropathic pain (8.0%) with a  mean pain score of  
0.86 and a median of  0. The inter rater reliability between 
the StEP scores and IASP diagnoses of  participants who 
had pain in the lower back region (marked with an As-
terix) was -0.074.
Codes and associated diagnoses of  known pathophysi-
ology of  all participants were reported.Only 16 (28.1%) 
participants could have their chronic pain adequately 
classified. There were 17 (29.8 %) participants who had 
codes not in the IASP manual and were assigned “code 
unallocated.” The majority of  patients 24 (42.1%) had 
codes were determining aetiology was not possible and 
were described as differing aetiology. No two participants 
had similar codes with 19/74 (25.7%) of  the participants 
Table 3: Participants with complete IASP codes and matching StEP scores
Non Neuropathic pain (n= 11) Neuropathic pain (n=5)
CODE DIAGNOSIS Scores on 
StEP
CODE DIAGNOSIS Scores on StEP
533.36 Ankolysing 
Spondylitis**




233.37 Pain of Psychological 
Origin in the Shoulder 
/Arm




854.08 Intermittent chronic anal 
pain
0 632.68 Ankolysing Spondylitis 10
4.X8 Occipital neuralgia 0 532.68 Ankolysing 
Spondylitis**
12
4.X8 Occipital neuralgia 0 533.68 Coccyx Pain 
Syndrome**
14
4.X8 Occipital neuralgia 0
534.28 Coccyx Pain 
Syndrome**
1
532.58 Osteoarthritis ** 1
634.38 Night cramps 2
634.28 Night cramps 2
634.08 Night cramps 2
Only 9 of  the 74 participants (12.2%) who reported CP 
had been previously diagnosed for their pain and all but 
one had some form of  pain treatment. Non steroidal an-
ti-inflammatory drugs (NSAIDS) were the primary form 
of  pain treatment with 6 of  the 8 participants who had 
had previous pain management having been managed 
with this drug class.
Significant associated factors in the unadjusted logistic 
regression model included reporting feeling ill [OR=10.4 
(5.8 – 18.6)], a past pain diagnosis [OR=3.6 (1.4 – 9.1)], 
current depressive episode [OR=0.2 (0.1 – 0.5)], previous 
pain treatment [OR=2.8 (1.1 – 7.3)] and worse scores in 
quality of  life domains in physical health [OR=0.6 (0.5 
– 0.7)], psychological [OR: 0.8 (0.7 – 0.9)]  and environ-
ment [OR=0.7 (0.6 – 0.8)].
In the adjusted model, feeling ill at review [OR=6.57 
(3.48 – 12.39)] as well as poor scores in the physical do-
main on the WHOQOL-BREF [OR= 0.71 (0.60- 0.83)] 
were found to be associated with CP. Other results from 
bi-variable analyses and logistic regression are reported in 
Tables 1 and 4, respectively.
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Discussion
This is the first study to explore the utility of  chronic 
pain classification among PLWHA in Uganda. The re-
sults presented above show that there was a lower preva-
lence of  chronic pain than has been documented in most 
other studies15. The prevalence of  CP was 21.5% which 
is less than other studies that have documented pain in 
our setting7,10,13. These studies looked at acute pain rather 
than chronic pain of  two weeks duration and this might 
explain the discrepancy in figures. Unlike other studies13, 
pain was found more in the region of  the lower back than 
in the lower limbs. The musculoskeletal system was most 
cited as being involved and this is similar to other studies 
done in our setting7. The majority of  patients reported 
pain of  medium intensity which is similar to studies done 
elsewhere7 but different from a review by Parker et al who 
found moderate to severe intensity15. No pain was asso-
ciated with more than two systems. This could have been 
due to difficulties among the study subjects to properly 
delineate which other systems/sites are involved. The du-
ration of  most pain lasting 1 to 6 months duration high-
lights the necessity of  not fixing a specified period for 
chronic pain in its definition. There is need for further 
studies to clearly differentiate between acute and chronic 
pain syndromes in HIV.
The study revealed the limitations in using the IASP clas-
sification of  chronic pain and the StEP for classification 
and description of  CP. Many studies6,28 have shown that 
pain in PLWHA is diverse with marked heterogeneity. 
Despite the fact that no two participants had similar di-
agnostic codes, the results probably reflect the tools poor 
suitability as classification tools rather than heterogeneity. 
For the majority of  participants it was difficult to describe 
the aetiology of  the chronic pain. Many participants were 
therefore classified as having differing aetiology. This was 
a key limitation of  the IASP classification as it isheavily 
reliant on describing the aetiology. Description of  aeti-
ology requires diagnostic tests which may not be easily 
available in resource limited settings. The IASP classifi-
cation also resulted in many participants having "code 
unallocated" which is critical for classification. Develop-
ment of  appropriate codes for resource limited settings 
in critical. Classification of  CP is however desirable as 
differing pain mechanisms with different severities were 
noted.The ability to differentiate neuropathic from non- 
neuropathic pain aids classification and thus improves on 
management. Our study found greater proportions of  
patients with CP had non-neuropathic pain. This differs 
from other studies that have documented larger propor-
tions of  neuropathic pain in PLWHA29,30. The reason for 
the differences could be due to the fact that many of  the 
participants were on HAART and thus had  better im-
mune statuses in comparison to other studies were poor 
immune status was associated with neuropathic pain. Of  
note however, is the fact that participants who had com-
plete IASP diagnostic codes for pain in the lower back 
region had poor correlation with pain mechanisms when 
assessed with StEP. This may reflect that the pain mecha-
nisms described are inconsistent and support an alternate 
theory of  neuropathic pain increasing despite HAART. 
There is need for further assessment to determine why 
StEP performs poorly in this population when differenti-
ating neuropathic from non neuropathic pain in patients 
with low back pain. A molecular description of  CP may 
also be an alternative way to describe CP in PLWHA31.
A key finding of  this study was the under diagnosis and 
under treatment of  pain in this population which has been 
Table 4: Logistic regression analysis for factors associated with chronic pain
Unadjusted Adjusted
Parameters OR (95% C.I)
P
OR (95% C.I) P
Reported feeling Ill 10.39 (5.81 – 18.59) 0.000 6.57 (3.48 – 12.39) 0.000
Depressive Episode 0.23 (0.11 – 0.47) 0.000 1.17 (0.41 – 3.34) 0.769
Past Pain Diagnosis 3.56 (1.39 – 9.12) 0.008 1.63 (0.48 – 5.59) 0.433
Physical health 0.63 (0.55 – 0.71) 0.000 0.71 (0.60 – 0.83) 0.000
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described before15,32. In this specialised centre when pain 
is diagnosed it is treated. The treatment however might 
not have been adequate considering many participants 
had ongoing pain. There is therefore need to integrate 
chronic pain management better pain diagnostic mea-
sures and associated treatments like cognitive behavioural 
therapy, physical therapy into HIV/AIDS care that takes 
into account various factors surrounding chronic pain 
care like co-morbid substance and other psychiatric dis-
orders28,33.
Another major finding of  this study was that CP in 
PLWHA is associated with worse quality of  life in 3 of  
the four domains further showing that chronic pain is de-
bilitating with increased morbidity. People without chron-
ic pain were more likely to have good qualityof  life when 
compared to those without chronic pain. With only 12% 
of  people with chronic pain having received a previous 
pain diagnosis or treatment further highlights the under 
diagnosis and treatment of  pain which has implications 
for quality of  life in this population.
Chronic pain also being associated with feeling ill is im-
portant as it may lead to increased use of  services. It 
there for highlights the need to diagnose and treat pain in 
PLWHA to better manage service delivery.
CP was not associated with a current or past major de-
pressive but was associated with worse outcomes in the 
psychological domain on quality of  life. Pain and depres-
sion have been shown to be highly associated but this is 
not the case in terms of  chronic pain in PLWHA and 
requires further review.
Various mechanisms have been postulated for pain in 
PLWHA including HAART regimes especially the D 
drugs, opportunistic infections, direct effect of  the virus 
on the central nervous system and immune function10.  In 
our study chronic pain was not associated with HAART 
use, HAART regimens or even CD4 counts which are 
markers for immune function. Chronic pain in HIV might 
have an alternative or multiple mechanisms that ensure it 
remains long after whatever insult caused it.
Limitations: The cross-sectional nature of  this study 
makes it difficult to examine causation and therefore bet-
ter designed studies might be required to explore this. 
Failure to clearly define the aetiology in some participants 
might have affected the classification. Studies where ae-
tiology is clearly determined to give better agreement 
with already existing codes in the IASP manual should 
be designed. More studies are required in order to better 
understand the associations and the impact of  the factors 
examined above on patients outcomes.
Conclusion
CP has again shown to be prevalent with worse outcomes 
on quality of  life. This study also highlights the limita-
tions of  tools like the IASP classification of  chronic pain 
and Standardised Evaluation of  Pain in diagnosis of  CP 
in PLWHA. There is need to design tools that can classify 
CP in PLWHA in order to prevent the under-diagnosis 
and under-treatment.
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